YAVEMBO
RegistradaNominativa · Brasil
Marca registrada: vale avaliar o risco de conflito
A marca "YAVEMBO" está registrada no Brasil. Se você usa ou pretende usar um nome similar, pode haver risco de conflito. Vale olhar classes, histórico e despachos antes de decidir o próximo passo.
Panorama da marca
- Situação INPI
- Deferimento da petição
- Tramitação até registro
- 1 ano e 8 meses
- Eventos no processo
- 4
- Última atualização
- 09 de abril de 2024
Dados do processo
- Titular
- Camurus AB
- Procurador
- P. B. (pessoa física)
- Número do processo
- 501674098
- Número de registro
- 501674098
- Natureza
- Madri Produto/Serviço
- Data do depósito
- 27 de abril de 2022
- Data do registro
- 26 de dezembro de 2023
- Válido até
- 27 de abril de 2032
Produtos e serviços cobertos
Pharmaceutical preparations; pharmaceutical preparations for injection; pharmaceutical preparation for subcutaneous injection; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone.;
Devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; devices for administration of pharmaceuticals for the treatment of tumours; devices for administration of pharmaceuticals for the treatment of carcinoid tumours; devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of esophageal bleeding; devices for administration of pharmaceuticals for metabolic disorders; devices for administration of pharmaceuticals for the treatment of acromegaly; devices for administration of pharmaceuticals for the treatment of polycystic liver disease; devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of injection fluids; devices for injection of injection depot; devices for subcutaneous administration of pharmaceuticals; devices for parenteral administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses.;
Linha do tempo do processo
4 eventosMovimentações mais recentes da marca “YAVEMBO” publicadas na Revista da Propriedade Industrial (RPI). O detalhe de cada despacho fica na consulta completa.
- Concessão / deferimento26 de dez. de 2023RPI 2764
Concessão de registro em designação
Detalhes na consulta completa
Saiba mais (+1 movimentação)
Veja o histórico completo de despachos desta marca e receba alertas de novas movimentações.
Ver histórico completoO que fazer se a sua marca se aproxima de "YAVEMBO"?
Conflitos de marcas no Brasil são resolvidos com base na anterioridade do depósito, nas classes de Nice e no segmento de atuação. O processo tem várias fases e pode ficar complexo quando o nome é parecido ou o mercado se cruza. Uma leitura cuidadosa ajuda a decidir se vale seguir, ajustar ou recuar.
A TrademarkIQ cruza histórico, decisões e padrões de aprovação por classe e setor em uma base com +6 milhões de processos brasileiros. Isso ajuda a enxergar o risco com mais contexto e a encontrar o melhor caminho comercial e jurídico para a sua marca.
Outras marcas do titular
Processos de marca no INPI em nome de Camurus Ab.
OCLAIZ
Deferimento da petição · Classe 5, 10
OCZYESA
Deferimento da petição · Classe 5, 10
BOCASIL
Extinção de registro pela expiração do prazo de vigência · Classe 5
BOCASIL
Extinção de registro pela expiração do prazo de vigência · Classe 44
BOCASIL
Extinção de registro pela expiração do prazo de vigência · Classe 42
Escritórios especializados
Notória Marcas e Patentes
Davilys Danques de Oliveira Cunha
Vilage Marcas e Patentes
Vigilância de marca
Seja avisado antes que vire problema
Monitoramento contínuo: receba um alerta a cada novo depósito que possa colidir com YAVEMBO ou com a sua marca — a tempo de se opor dentro do prazo.
Monitorar marcaDados actualizados a partir de uma base com +6 milhões de marcas brasileiras analisadas. Esta página é informativa e não substitui parecer jurídico, mas ajuda a orientar a decisão com mais contexto comercial e técnico.
